-----BEGIN PRIVACY-ENHANCED MESSAGE-----
Proc-Type: 2001,MIC-CLEAR
Originator-Name: webmaster@www.sec.gov
Originator-Key-Asymmetric:
 MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen
 TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB
MIC-Info: RSA-MD5,RSA,
 Aw0iVtXG3YNhSzfiNvmfu4sPhpaVLs6XqkMblNCr8l1lYOvoM3grRpdqtJ4f6Gzr
 51+ebZsksgf5Lj0y47C8YQ==

<SEC-DOCUMENT>0000842023-09-000028.txt : 20090804
<SEC-HEADER>0000842023-09-000028.hdr.sgml : 20090804
<ACCEPTANCE-DATETIME>20090804092227
ACCESSION NUMBER:		0000842023-09-000028
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20090804
ITEM INFORMATION:		Results of Operations and Financial Condition
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20090804
DATE AS OF CHANGE:		20090804

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			TECHNE CORP /MN/
		CENTRAL INDEX KEY:			0000842023
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				411427402
		STATE OF INCORPORATION:			MN
		FISCAL YEAR END:			0630

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-17272
		FILM NUMBER:		09981871

	BUSINESS ADDRESS:	
		STREET 1:		614 MCKINLEY PL N E
		CITY:			MINNEAPOLIS
		STATE:			MN
		ZIP:			55413
		BUSINESS PHONE:		6123798854

	MAIL ADDRESS:	
		STREET 1:		614 MCKINLEY PLACE NE
		CITY:			MINNEAPOLIS
		STATE:			MN
		ZIP:			55413
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>k8q.txt
<DESCRIPTION>8-K
<TEXT>
                      SECURITIES AND EXCHANGE COMMISSION
                            WASHINGTON, D.C. 20549

                                FORM 8-K

                              CURRENT REPORT

                  PURSUANT TO SECTION 13 OR 15(d) OF THE
                     SECURITIES EXCHANGE ACT OF 1934

    Date of report (Date of earliest event reported): August 4, 2009

                            TECHNE CORPORATION
             (Exact Name of Registrant as Specified in Charter)


       Minnesota                     0-17272             41-1427402
(State or Other Jurisdiction       (Commission         I.R.S. Employer
of Incorporation)                  File Number)      Identification No.)

                614 Mckinley Place NE
                   Minneapolis, MN                       55413
       (Address of Principal Executive Offices)       (Zip Code)

     Registrant's telephone number, including area code:  (612) 379-8854

                              Not Applicable
      (Former Name or Former Address, if changed since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligations of the registrant under any
of the following provisions:

/ /   Written communications pursuant to Rule 425 under the Securities Act
      17 CFR 230.425)

/ /   Soliciting material pursuant to Rule 14a-12 under the Exchange Act
      (17 CFR 240.14a-12)

/ /   Pre-commencement communications pursuant to Rule 14d-2(b) under the
      Exchange Act (17 CFR 240.14d-2(b))

/ /   Pre-commencement communications pursuant to Rule 13e-4(c) under the
      Exchange Act (17 CFR 240.13e-4(c))


<PAGE>



Item 2.02  Results of Operations and Financial Condition

A copy of the press release issued by Techne Corporation on August 4,
2009, describing the results of operations for the quarter and fiscal year
ended June 30, 2009 and its financial condition as of June 30, 2009,
is attached hereto as Exhibit 99.1.

Segment information for Techne Corporation for the quarter and fiscal year
ended June 30, 2009 which has been included on Techne Corporation's
website (www.techne-corp.com), is attached hereto as Exhibit 99.2.

The information in this Form 8-K and the Exhibits attached hereto shall not
be deemed "filed" for purposes of Section 18 of the Securities Exchange Act
of 1934, as amended (the "Exchange Act"), or otherwise subject to the
liabilities of that section, nor shall it be deemed incorporated by reference
in any filing under the Securities Act of 1933 or the Exchange Act, except as
expressly set forth by specific reference in such filing.


Item 9.01 Financial Statements and Exhibits

     (d) Exhibits

         99.1 Press Release dated August 4, 2009.

         99.2 Segment information for the quarter and fiscal year ended
              June 30, 2009.






                            SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the
Registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.


Dated: August 4, 2009                 TECHNE CORPORATION
                                      By: /s/ Thomas E. Oland
                                      ---------------------------
                                      Name: Thomas E. Oland
                                      Title: President and Chief
                                        Executive Officer



                          EXHIBIT INDEX

    Exhibit No. Description
    ----------- -----------
       99.1     Press release of Techne Corporation dated August 4, 2009.

       99.2     Segment information for Techne Corporation for the quarter
                and fiscal year ended June 30, 2009.

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>fy09release.txt
<DESCRIPTION>PRESS RELEASE DATED AUGUST 4, 2009
<TEXT>

    TECHNE CORPORATION RELEASES UNAUDITED FOURTH QUARTER
          RESULTS FOR FISCAL YEAR 2009

Minneapolis/August 4, 2009/-- Techne Corporation's (NASDAQ: TECH)
consolidated net earnings for the quarter ended June 30, 2009
decreased 6.9% to $25.4 million or $.68 per diluted share compared
with $27.3 million or $.70 per diluted share for the quarter ended
June 30, 2008.  For the fiscal year ended June 30, 2009, Techne's
consolidated net earnings increased 1.6% to $105.2 million or $2.78
per diluted share compared with $103.6 million or $2.64 per diluted
share for the fiscal year ended June 30, 2008.  Net earnings as a
percentage of net sales were 39.9% for the fiscal year ended June 30,
2009 as compared to 40.2% in fiscal 2008.

Foreign currency fluctuations and general economic conditions
continued to have a negative impact on consolidated net sales and
earnings in the quarter ended June 30, 2009. The change in exchange
rates used to convert foreign currencies (primarily British pound
sterling and euros) to U.S. dollars reduced net earnings by $1.1
million ($.03 per diluted share) for the quarter and $4.5 million
($.12 per diluted share) for fiscal year 2009, as compared to the same
periods in fiscal 2008.

Consolidated net sales for the quarter and fiscal year ended June 30,
2009 were $64.9 million and $264.0 million, respectively. This was a
4.2% decrease and a 2.5% increase from the quarter and fiscal year
ended June 30, 2008, respectively. Consolidated net sales were
negatively affected by the strength of the U.S. dollar as compared to
foreign currencies. Excluding the effect of changes in foreign
currency exchange rates, consolidated net sales decreased 0.9% for the
quarter ended June 30, 2009 and increased 5.9% for the fiscal year
ended June 30, 2009, from the comparable prior year periods.

Biotechnology net sales, which include sales by R&D Systems'
Biotechnology Division, R&D Systems China and BiosPacific, were $42.3
million for the quarter ended June 30, 2009, a decrease of 0.6% from
the quarter ended June 30, 2008.  Biotechnology sales were $173.9
million for the fiscal year ended June 30, 2009, an increase of 5.0%
over the same period last year.  North American biotechnology sales to
industrial pharmaceutical and biotechnology customers declined
approximately 2% during the fourth quarter of fiscal 2009.  The
Company attributes the lower fourth quarter sales growth rate to
continued customer caution in a time of economic uncertainty.

R&D Europe's net sales for the quarter and fiscal year ended June 30,
2009 were $18.0 million and $72.5 million, decreases of 14.3% and
4.2%, respectively, from the same prior-year periods.  R&D Europe's
net sales decreased 3.6% for the quarter ended June 30, 2009 and
increased 7.2% for the fiscal year ended June 30, 2009 when measured
at currency rates in effect in the comparable prior periods.   R&D
Europe's net sales for the quarter ended June 30, 2009 were affected
by the timing of the Easter holiday in Europe, which occurred in the
third quarter of fiscal 2008.

Hematology net sales for the quarter and fiscal year ended June 30,
2009 were $4.6 million and $17.5 million, increases of 8.9% and 9.2%,
respectively, compared to the quarter and fiscal year ended June 30,
2008.

Consolidated gross margins were 77.4% and 79.0% for the quarter and
fiscal year ended June 30, 2009, respectively, compared to 79.5% for
both the quarter and fiscal year ended June 30, 2008, respectively.
The decreases in gross margins in the quarter and fiscal year ended
June 30, 2009 were primarily caused by lower gross margins in Europe
resulting from comparatively unfavorable exchange rates. Consolidated
gross margins for the quarter ended June 30, 2009 also decreased from
the quarter ended March 31, 2009 as a result of a change in sales mix
from higher margin Biotechnology Division sales to lower margin
Hematology Division and R&D Europe sales.

Selling, general and administrative expenses for the quarter and
fiscal year ended June 30, 2009 decreased $1.4 million (15.9%) and
$3.6 million (9.7%), respectively from the quarter and fiscal year
ended June 30, 2008. The decrease in selling, general and
administrative expenses from the comparable prior-year periods were
the result of the following (in thousands):

                                          Quarter  Fiscal Year
                                          -------  -----------
Reduction in profit sharing expense       $(1,816)   $(3,759)
Change in exchange rates to convert
 foreign expenses to U.S. dollars            (486)    (2,024)
Legal expenses                                587        786
Stock option expense                          111       (249)
Other, including annual wage, salary
 and benefits increases                       178      1,695
                                          -------    -------
                                          $(1,426)   $(3,551)
                                          =======    =======

Research and development expenses increased $187,000 (3.2%) and $1.2
million (5.2%), respectively, for the quarter and fiscal year ended
June 30, 2009 from the comparable prior-year periods.

Interest income decreased $1.7 million and $4.6 million for the
quarter and fiscal year ended June 30, 2009, respectively, from the
comparable prior-year periods, primarily as a result of lower rates of
return on cash and available-for-sale investments and, to a lesser
extent, to lower cash and available-for-sale investment balances.

The effective tax rates for the quarter and fiscal year ended June 30,
2009 were 32.2% and 32.3%, respectively, as compared to effective tax
rates of 32.7% for both of the same prior-year periods.

In November 2007, the Company's Board of Directors authorized the
repurchase and retirement of up to $150 million of the Company's
common stock.  In April 2009, an additional $60 million was authorized
for repurchase and retirement of common stock. The Company repurchased
approximately 33,000 shares of its common stock during the fourth
quarter of fiscal 2009 for approximately $1.8 million. Approximately
$67.5 million remains available for the repurchase of shares under
these authorizations.


Forward Looking Statements:

This earnings release contains forward-looking statements within the
meaning of the Private Litigation Reform Act. These statements involve
risks and uncertainties that may affect the actual results of
operations. The following important factors, among others, have
affected and, in the future, could affect the Company's actual
results: the introduction and acceptance of new biotechnology and
hematology products, the levels and particular directions of research
by the Company's customers, the impact of the growing number of
producers of biotechnology research products and related price
competition, general economic conditions, the retention of hematology
OEM and proficiency survey business, the impact of currency exchange
rate fluctuations, and the costs and results of research and product
development efforts of the Company and of companies in which the
Company has invested or with which it has formed strategic
relationships.

For additional information concerning such factors, see the Company's
annual report on Form 10-K and quarterly reports on Form 10-Q as filed
with the Securities and Exchange Commission.  We undertake no
obligation to update or revise any forward-looking statements we make
in this release due to new information or future events.  Investors
are cautioned not to place undue emphasis on these statements.

                *  *  *  *  *  *  *  *  *  *  *  *

Techne Corporation has two operating subsidiaries:  Research and
Diagnostic Systems, Inc. (R&D Systems) of Minneapolis, Minnesota and
R&D Systems Europe, Ltd. (R&D Europe) of Abingdon, England.  R&D
Systems is a specialty manufacturer of biological products.  R&D
Systems has two subsidiaries, BiosPacific, Inc. (BiosPacific), located
in Emeryville, California and R&D Systems China Co. Ltd., (R&D China),
located in Shanghai, China.  BiosPacific is a worldwide supplier of
biologics to manufacturers of in vitro diagnostic systems and
immunodiagnostic kits. R&D China and R&D Europe distribute
biotechnology products.


Contact:  Greg Melsen, Chief Financial Officer
          Kathy Backes, Controller
         (612) 379-8854



                            TECHNE CORPORATION
                 CONSOLIDATED STATEMENTS OF EARNINGS
                (In thousands, except per share data)
                              (Unaudited)

                                  QUARTER ENDED   FISCAL YEAR ENDED
                                ----------------  ------------------
                                6/30/09  6/30/08   6/30/09   6/30/08
                                -------  -------  --------  --------
Net sales                       $64,890  $67,769  $263,956  $257,420
Cost of sales                    14,656   13,888    55,488    52,889
                                -------  -------  --------  --------
Gross margin                     50,234   53,881   208,468   204,531
  Operating expenses:
   Selling, general and
    administrative                7,560    8,986    33,164    36,715
   Research and development       5,999    5,812    23,564    22,394
   Amortization of
    intangible assets               240      282       960     1,135
                                -------  -------  --------  --------
      Total operating expenses   13,799   15,080    57,688    60,244
                                -------  -------  --------  --------
Operating income                 36,435   38,801   150,780   144,287

Other income (expense):
  Interest income                 1,038    2,783     7,634    12,188
  Other non-operating
   expense, net                     (49)  (1,079)   (3,051)   (2,644)
                                -------  -------  --------  --------
       Total other income           989    1,704     4,583     9,544
                                -------  -------  --------  --------
Earnings before income taxes     37,424   40,505   155,363   153,831
Income taxes                     12,038   13,248    50,121    50,273
                                -------  -------  --------  --------
Net earnings                    $25,386  $27,257  $105,242  $103,558
                                =======  =======  ========  ========
Earnings per share:
 Basic                          $  0.68  $  0.70  $   2.78  $   2.65
 Diluted                        $  0.68  $  0.70  $   2.78  $   2.64
Weighted average common
 shares outstanding:
 Basic                           37,248   38,665    37,802    39,139
 Diluted                         37,332   38,788    37,900    39,247


                           TECHNE CORPORATION
                       CONSOLIDATED BALANCE SHEETS
                              (In thousands)
                                (Unaudited)
                                                    6/30/09   6/30/08
                                                   --------  --------
ASSETS
Cash and equivalents                               $160,940  $166,992
Short-term available-for-sale investments            41,947    39,353
Trade accounts receivable                            29,516    31,747
Other receivables                                     1,637     1,585
Inventory                                            11,269     9,515
Other current assets                                 10,158     9,241
                                                   --------  --------
  Current assets                                    255,467   258,433
                                                   --------  --------

Available-for-sale investments                       61,863    87,384
Property and equipment, net                         100,133   101,722
Goodwill and intangible assets, net                  28,072    29,032
Other non-current assets                             26,470    30,798
                                                   --------  --------
  Total assets                                     $472,005  $507,369
                                                   ========  ========
LIABILITIES
Current liabilities                                $ 15,523  $ 20,239
Stockholders' equity                                456,482    487,13
                                                   --------  --------
  Total liabilities and equity                     $472,005  $507,369
                                                   ========  ========


</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.2
<SEQUENCE>3
<FILENAME>seg609.txt
<DESCRIPTION>SEGMENT RESULTS
<TEXT>
                                   SEGMENT INFORMATION
                         TECHNE CORPORATION AND SUBISIDARIES
                       (in thousands of $'s, except per share data)
<CAPTION>
<TABLE>
                                    Fiscal 2009                 Increase (Decrease) From Fiscal 2008
               ------------------------------------------------ ---------------------------------------
                First  Second   Third  Fourth          Percent   First  Second   Third  Fourth
               Quarter Quarter Quarter Quarter  YTD    Of Sales Quarter Quarter Quarter Quarter   YTD
               ------- ------- ------- ------- ------- -------- ------- ------- ------- -------  ------
<S>            <C>     <C>     <C>     <C>     <C>     <C>      <C>     <C>     <C>     <C>      <C>
Sales           69,324  61,876  67,866  64,890 263,956   100%    11,337    (266) (1,656) (2,879)  6,536
Cost of sales   13,086  13,430  14,316  14,656  55,488    21%       982     679     170     768   2,599
               ------- ------- ------- ------- ------- -------- ------- ------- ------- -------  ------
Gross margin    56,238  48,446  53,550  50,234 208,468    79%    10,355    (945) (1,826) (3,647)  3,937

Gross margin
 percentage      81.1%   78.3%   78.9%   77.4%   79.0%

SG&A expense     8,840   9,703   7,061   7,560  33,164    13%       750    (942) (1,933) (1,426) (3,551)
R&D expense      5,910   5,846   5,809   5,999  23,564     9%       729     284     (30)    187   1,170
Amortization
 expense           240     240     240     240     960     -        (48)    (42)    (43)    (42)   (175)
Interest income (2,887) (2,205) (1,504) (1,038) (7,634)   (3%)      111   1,047   1,651   1,745   4,554
Other non-oper-
 ating ex., net  1,187     712   1,103      49   3,051     1%       618     139     680  (1,030)    407
               ------- ------- ------- ------- ------- -------- ------- ------- ------- -------  ------
                13,290  14,296  12,709  12,810  53,105    20%     2,160     486     325    (566)  2,405
               ------- ------- ------- ------- ------- -------- ------- ------- ------- -------  ------
Earnings before
 income taxes   42,948  34,150  40,841  37,424 155,363    59%     8,195  (1,431) (2,151) (3,081)  1,532
Income taxes    14,355  10,528  13,200  12,038  50,121    19%     2,674  (1,414)   (202) (1,210)   (152)
               ------- ------- ------- ------- ------- -------- ------- ------- ------- -------  ------
                28,593  23,622  27,641  25,386 105,242    40%     5,521     (17) (1,949) (1,871)  1,684
               ======= ======= ======= ======= ======= ======== ======= ======= ======= =======  ======
Diluted earnings
 per share         .74     .62     .74     .68    2.78
Weighted average
 diluted shares
 outstanding    38,747  37,992  37,499  37,332  37,900

</TABLE>

                                         BIOTECHNOLOGY  (1)
                                       (in thousands of $'s)
<CAPTION>
<TABLE>
                                    Fiscal 2009                 Increase (Decrease) From Fiscal 2008
               ------------------------------------------------ ---------------------------------------
                First  Second   Third  Fourth          Percent   First  Second   Third  Fourth
               Quarter Quarter Quarter Quarter  YTD    Of Sales Quarter Quarter Quarter Quarter   YTD
               ------- ------- ------- ------- ------- -------- ------- ------- ------- -------  ------
<S>            <C>     <C>     <C>     <C>     <C>     <C>      <C>     <C>     <C>     <C>      <C>
Sales           53,899  48,643  53,718  49,734 205,994    100%    8,571   2,067     806    (261) 11,183
Intersegment
 sales          (7,762) (8,311) (8,579) (7,429)(32,081)          (1,315)   (878)   (757)     17  (2,933)
               ------- ------- ------- ------- -------          ------- ------- ------- -------  ------
                46,137  40,332  45,139  42,305 173,913            7,256   1,189      49    (244)  8,250

Cost of sales   10,247  11,090  11,080  10,311  42,728     21%    1,250   1,478     371      64   3,163
Intersegment
 sales          (7,461) (8,339) (8,494) (7,454)(31,748)          (1,287)   (909)   (739)    284  (2,651)
               ------- ------- ------- ------- -------          ------- ------- ------- -------  ------
                 2,786   2,751   2,586   2,857  10,980              (37)    569    (368)    348     512

Gross margin    43,351  37,581  42,553  39,448 162,933     79%    7,293     620     417    (592)  7,738

Gross margin
 percentage      81.0%   77.2%   79.4%   79.3%   79.3%

SG&A expense     5,141   5,418   4,262   4,214  19,035      9%      517    (116)   (995) (1,352) (1,946)
R&D expense      5,717   5,643   5,622   5,810  22,792     11%      715     275     (18)    188   1,160
Amortization
 expense           240     240     240     240     960     --       (48)    (42)    (43)    (42)   (175)
Interest, net   (1,084)   (970)   (853)   (743) (3,650)    (1%)     173     339     432     245   1,189
Other expense       (2)      1       1       2       2      --      (36)    (11)      6    (387)   (428)
               ------- ------- ------- ------- ------- -------- ------- ------- ------- -------  ------
                10,012  10,332   9,272   9,523  39,139     19%    1,321     445    (618) (1,348)   (200)
               ------- ------- ------- ------- ------- -------- ------- ------- ------- -------  ------
Pretax result   33,339  27,249  33,281  29,925 123,794     60%    5,972     175   1,035     756   7,938
               ======= ======= ======= ======= ======= ======== ======= ======= ======= =======  ======
</TABLE>

(1) Includes R&D Systems' Biotechnology Division, BiosPacific, Inc.
and R&D China



                                    R&D SYSTEMS EUROPE
                                   (in thousands of Br. pounds)
<CAPTION>
<TABLE>
                                    Fiscal 2009                 Increase (Decrease) From Fiscal 2008
               ------------------------------------------------ ---------------------------------------
                First  Second   Third  Fourth          Percent   First  Second   Third  Fourth
               Quarter Quarter Quarter Quarter  YTD    Of Sales Quarter Quarter Quarter Quarter   YTD
               ------- ------- ------- ------- ------- -------- ------- ------- ------- -------  ------
<S>            <C>     <C>     <C>     <C>     <C>     <C>      <C>     <C>     <C>     <C>      <C>
Sales           10,175  11,197  12,716  11,134  45,222    100%    2,570   1,896   2,536     569   7,571
Cost of sales    4,260   5,361   6,540   5,683  21,844     48%      805   1,308   2,148   1,197   5,458
               ------- ------- ------- ------- ------- -------- ------- ------- ------- -------  ------
Gross margin     5,915   5,836   6,176   5,451  23,378     52%    1,765     588     388    (628)  2,113

Gross margin
 percentage      58.1%   52.1%   48.6%   49.0%   51.7%

SG&A expense     1,224   1,364   1,191   1,188   4,967     11%      110      88      28     (65)    161
Interest income   (790)   (583)   (235)   (102) (1,710)    (4%)    (107)    190     527     638   1,248
Exchange loss/
 (gain)            260     (35)    163    (368)     20      1%      356      46     393    (359)    436
               ------- ------- ------- ------- ------- -------- ------- ------- ------- -------  ------
                   694     746   1,119     718   3,277      8%      359     324     948     214   1,845
               ------- ------- ------- ------- ------- -------- ------- ------- ------- -------  ------
Pretax result    5,221   5,090   5,057   4,733  20,101     44%    1,406     264    (560)   (842)    268
               ======= ======= ======= ======= ======= ======== ======= ======= ======= =======  ======

</TABLE>

                                   R&D SYSTEMS EUROPE
                                  (in thousands of $'s)
<CAPTION>
<TABLE>
                                    Fiscal 2009                 Increase (Decrease) From Fiscal 2008
               ------------------------------------------------ ---------------------------------------
                First  Second   Third  Fourth          Percent   First  Second   Third  Fourth
               Quarter Quarter Quarter Quarter  YTD    Of Sales Quarter Quarter Quarter Quarter   YTD
               ------- ------- ------- ------- ------- -------- ------- ------- ------- -------  ------
<S>            <C>     <C>     <C>     <C>     <C>     <C>      <C>     <C>     <C>     <C>      <C>
Sales           18,941  17,284  18,293  18,023  72,541    100%    3,492  (1,743) (1,933) (3,010) (3,194)
Cost of sales    7,931   8,274   9,405   9,430  35,040     48%      911     (19)    679     508   2,079
               ------- ------- ------- ------- ------- -------- ------- ------- ------- -------  ------
Gross margin    11,010   9,010   8,888   8,593  37,501     52%    2,581  (1,724) (2,612) (3,518) (5,273)

Gross margin
 percentage      58.1%   52.1%   48.6%   47.7%   51.7%

SG&A expense     2,283   2,094   1,714   1,876   7,967     11%       21    (505)   (597)   (619) (1,700)
Interest income (1,471)   (906)   (338)    (28) (2,743)    (4%)     (84)    670   1,176   1,444   3,206
Exchange loss      476       5     238    (687)     32      1%      674     170     695    (670)    869
               ------- ------- ------- ------- ------- -------- ------- ------- ------- -------  ------
                 1,288   1,193   1,614   1,161   5,256      8%      611     335   1,274     155   2,375
               ------- ------- ------- ------- ------- -------- ------- ------- ------- -------  ------
Pretax result    9,722   7,817   7,274   7,432  32,245     44%    1,970  (2,059) (3,886) (3,673) (7,648)
               ======= ======= ======= ======= ======= ======== ======= ======= ======= =======  ======

</TABLE>

                                            HEMATOLOGY
                                       (in thousands of $'s)
<CAPTION>
<TABLE>
                                    Fiscal 2009                 Increase (Decrease) From Fiscal 2008
               ------------------------------------------------ ---------------------------------------
                First  Second   Third  Fourth          Percent   First  Second   Third  Fourth
               Quarter Quarter Quarter Quarter  YTD    Of Sales Quarter Quarter Quarter Quarter   YTD
               ------- ------- ------- ------- ------- -------- ------- ------- ------- -------  ------
<S>            <C>     <C>     <C>     <C>     <C>     <C>      <C>     <C>     <C>     <C>      <C>
Sales            4,246   4,260   4,434   4,562  17,502    100%      589     288     228     375   1,480
Cost of sales    2,369   2,405   2,325   2,369   9,468     54%      108     129    (141)    (88)      8
               ------- ------- ------- ------- ------- -------- ------- ------- ------- -------  ------
Gross margin     1,877   1,855   2,109   2,193   8,034     46%      481     159     369     463   1,472

Gross margin
 percentage      44.2%   43.5%   47.6%   48.1%   45.9%

SG&A expense       436     398     310     319   1,463      9%      (31)    (89)   (179)   (241)   (540)
R&D expense        193     203     187     189     772      4%       14       9     (12)     (1)     10
Interest, net     (102)    (91)    (80)    (72)   (345)    (2%)      18      34      43      21     116
               ------- ------- ------- ------- ------- -------- ------- ------- ------- -------  ------
                   527     510     417     436   1,890     11%        1     (46)   (148)   (221)   (414)
               ------- ------- ------- ------- ------- -------- ------- ------- ------- -------  ------
Pretax result    1,350   1,345   1,692   1,757   6,144      35%     480     205     517     684   1,886
               ======= ======= ======= ======= ======= ======== ======= ======= ======= ======= =======

</TABLE>

                                    CORPORATE AND OTHER (2)
                                     (in thousands of $'s)
<CAPTION>
<TABLE>
                                    Fiscal 2009         Increase (Decrease) From Fiscal 2008
               --------------------------------------- ---------------------------------------
                First  Second   Third  Fourth          First  Second   Third  Fourth
               Quarter Quarter Quarter Quarter  YTD    Quarter Quarter Quarter Quarter   YTD
               ------- ------- ------- ------- ------- ------- ------- ------- -------  ------
<S>            <C>     <C>     <C>     <C>     <C>     <C>     <C>     <C>     <C>      <C>
Interest income    230     238     233     195     896     (4)     (4)     --     (35)    (43)
Rental income       99     131     115     136     481     32      20      24       1      77
               ------- ------- ------- ------- ------- ------- ------- ------- -------  ------
                   329     369     348     331   1,377     28      16      24     (34)     34

SG&A expense       980   1,793     775   1,151   4,699    243    (232)   (162)    786     635
Other-Building
 expenses          553     551     573     531   2,208      9     (49)    (60)     (7)   (107)
Other-Equity
 Investment losses 259     286     406     339   1,290      3      49      63      35     150
               ------- ------- ------- ------- ------- ------- ------- ------- -------  ------
                 1,792   2,630   1,754   2,021   8,197    255    (232)   (159)    814     678
               ------- ------- ------- ------- ------- ------- ------- ------- -------  ------
Pretax result   (1,463) (2,261) (1,406) (1,690) (6,820)  (227)    248     183    (848)   (644)
               ======= ======= ======= ======= ======= ======= ======= ======= =======  ======
</TABLE>

(2) Unallocated corporate expenses and Techne's share of
losses by Hemerus Medical, LLC and Nephromics, LLC.
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
-----END PRIVACY-ENHANCED MESSAGE-----
